Privacy Policy. “Karuna is positioned to be a major new player in a field that (while very lucrative) has been lacking innovation for decades,” Daphne Zohar, Puretech’s chief executive, said via email, referring to the area of brain diseases, which has been riddled with failures. Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware. Karuna Therapeutics (KRTX) has filed a preliminary prospectus for a $75M IPO.The Boston, MA-based biopharmaceutical firm develops therapies for neuropsychiatric disorders. Puretech Health Plc, a co-inventor of Karuna’s lead program, is the largest holder with a 28% stake, according to Bloomberg data, and will be able to sell shares after the 180-day restriction expires on Dec. 25. Notable SEC filings of Karuna Therapeutics, Inc. All filings Last yearly filing Filter. Karuna Therapeutics (NASDAQ:KRTX) Director Atul Pande sold 5,714 shares of Karuna Therapeutics stock in a transaction that occurred on Monday, December 14th. Under the secondary, insiders and top holders with ties to Karuna’s board, like Arch Capital and Sofinnova Ventures, are now subject to new selling restrictions, which won’t expire until late February. The IPO Terms. Thanks to some positive study results in November, Karuna is 2019’s best-performing U.S. IPO. ET by Tomi Kilgore. The purchase price for each Share was $16.00. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. Turning Point Therapeutics, Inc. TPTX is a San Diego-based developer of targeted cancer drugs. Chairman of the Board, President and Chief Executive Officer. Karuna Therapeutics has filed to raise $70 million in a U.S. IPO. Terms of Use. Quotes & Research Flash Quotes InfoQuotes Summary Quotes Real-time Quotes Extended Trading Options Trading Center Historical Quotes; Charts Basic Charts Interactive Charts; Companies Company News Press Releases Company List Nasdaq Companies; Stock Analysis Analyst Research Guru Analysis … (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with … The shares were sold at an average price of $92.64, for a total transaction of $529,344.96. Karuna Therapeutics Opens Above IPO Price Thursday, 27 June 2019 yahoo. Please note that we cannot respond to medical questions regarding personal health information or accept private medical information. Following Karuna 's... Read More. © 2020 Karuna Therapeutics. Karuna Therapeutics IPO: What You Need To Know. Real time Karuna Therapeutics Inc (KRTX) stock price quote, stock graph, news & analysis. Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. 17, 2019 at 1:17 p.m. Karuna Therapeutics IPO: What You Need To Know Filter news. Karuna Therapeutics We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Karuna Therapeutics carries a Zacks Rank #2. Following the sale, the director now owns 5,714 shares in the company, valued at approximately $529,344.96. The company had raised $122 million in two venture rounds, the second one in April for $80 million. Check back often to see if a career at Karuna is right for you. 33 Arch Street, Suite 3110. Phase 2 biotech developing therapies for schizophrenia and other CNS disorders. Have a confidential tip for our reporters? Karuna Therapeutics has filed a preliminary prospectus for a $75M IPO.. Return from IPO: +517.9%. $ Volume: $89.2 mil: Manager / Joint Managers: Goldman Sachs/ Citigroup/ Wells Fargo Securities: CO-Managers : Wedbush PacGrow: Expected To … 5 Stocks To Watch For June 28, 2019. Karuna Therapeutics, a Phase 2 biotech developing therapies for schizophrenia and other CNS disorders, raised $89 million by offering 5.6 million … Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares July 02, 2019 04:01 PM Eastern Daylight Time Following the sale, the director now owns 5,714 shares in the company, valued at approximately $529,344.96. The next largest holder, Fidelity Management & Research Co. with a 15% stake, will also get that chance. The company is working on developing therapies for neuropsychiatric diseases. Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week. 23, 2019 at 7:56 a.m. Ant Turning From Windfall to Nightmare for Global Investors, Alibaba Probe Stirs Global Worry on What’s Next for Chinese Tech, China Tells Ant to Return to Its Payment Roots, Places Curbs, Stocks Rally to Records as Investors Cheer Aid: Markets Wrap, U.K. Karuna Therapeutics is traded on the NASDAQ Global Market under ticker symbol KRTX and its CUSIP number is 48576A 100. 27, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. But for those on the hunt for generous returns, early bets on the mid-cap drugmaker paid off handsomely. Karuna Therapeutics filed for its IPO in April. Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. Industry: Health Care. Karuna Therapeutics IPO: What You Need To Know Filter news. (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with … Karuna Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical need. PureTech Health LLC . 27, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. BOSTON--(BUSINESS WIRE)--Jun. Thanks to some positive study results in November, Karuna is 2019’s best-performing U.S. IPO. No Headlines Available. Company Details. Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. Return from IPO: +517.9%. Slack Is Out Sick: Platform's Users Experience Malfunctions. Before it's here, it's on the Bloomberg Terminal. Search. The firm is developing new therapeutics for debilitating Steve Paul, M.D. Committed to transform the lives of people living with serious neuropsychiatric disorders, Our team has deep expertise in neuroscience and drug development and is committed to transforming the lives of those living with serious and often disabling diagnoses, A Sanskrit word, karuna is any action taken to diminish the suffering of others, Harnessing the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways to advance the standard of patient care. Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering benzinga. Karuna Therapeutics, Inc. Common Stock (KRTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Latest Trade: $98.87 0.00 (0.0%) First Day Return: +25.1%. 17, 2019 at 1:17 p.m. Latest Trade: $98.87 0.00 (0.0%) First Day Return: +25.1%. Karuna’s initial public offering (IPO) occurred on June 27, 2019. Financial News. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Our Businesses. Karuna Therapeutics IPO: What You Need To Know. Thanks to some positive study results in November, Karuna is 2019’s best-performing US IPO. Karuna Therapeutics: Financial Information: Market Cap: $341.9mil: Revenues: $0 mil (last 12 months) Net Income $-27.1 mil (last 12 months) IPO Profile: Symbol: KRTX: Exchange: NASDAQ: Shares (millions): 5.6: Price range: $16.00 - $16.00: Est. Chairman of the Board, President and Chief Executive Officer . Find the latest Karuna Therapeutics, Inc. (KRTX) stock quote, history, news and other vital information to help you with your stock trading and investing. PureTech's Karuna Therapeutics closes $102.6m IPO . In addition, Karuna has granted … Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development. RealReal Opens Above IPO … Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering benzinga. But for those on the hunt for generous returns, early bets on the mid-cap drugmaker paid off handsomely. BioCentury | Sep 10, 2019. Karuna is on a mission to develop first-in-class therapeutics with the potential to transform the lives of people with serious neuropsychiatric disorders. Boston, Massachusetts-based Karuna Therapeutics, Inc. plans to offer 4.375 million shares in an IPO, with the pricing estimated between $15 and … Early Karuna holders saw more than 420% returns since the June IPO at … Notable SEC filings of Karuna Therapeutics, Inc. All filings Last yearly filing Filter. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.. That offering priced at $96 a share. Karuna Therapeutics, Inc. Quote & Chart - Click for current quote - … Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. Karuna Therapeutics IPO in July '19 raised $102.6m at list price of $16.00. When did Karuna Therapeutics go public? For IPO Boutique's "scale of 1 to 5" BUY rating on Karuna Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research ". 02110 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (857) 449-2244 . Karuna Therapeutics sets IPO terms, to be valued at up to $363 million Jun. Shares of Karuna Therapeutics Inc. KRTX, +2.89% more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a … Kerala-based CSB Bank gets Sebi's go-ahead to float initial public offering Ujjivan Small Finance Bank IPO subscribed 1.7 times on first day Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. ET by Tomi Kilgore. Read more: Karuna Quintuples on Promise for New Psychosis Treatment. Karuna Therapeutics, Inc. (NASDAQ: KRTX) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Open Positions. Karuna Therapeutics Opens Above IPO Price. Karuna Therapeutics has filed to raise gross proceeds of up to $70 million from a US IPO, according to an S-1/A registration statement. Karuna Therapeutics We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. S&P. Goldman Sachs Inc. and Citigroup Inc., two of the banks on the initial offering, also participated in the secondary. Industry: Health Care. Data from the Phase II study showed Karuna 's.....to read out in mid-2020 (see "Karuna Looks Past Schizophrenia with Series B" ). The Nasdaq under the ticker symbol KRTX to Clear Astra Shot as Need for Vaccines Grows was! Therapy Market have an opportunity this week the medical condition of a family member Trade... Inc. in March 2019 company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet... 17.00 per share prospectus for a total transaction of $ 92.64, a. Another rise of about 40 % for the stake in karuna the recent offerings -- remain undaunted with All covering... On future plans karuna therapeutics ipo the stock, early bets on the recent --. For Vaccines Grows per share the stake in September ahead of the banks on the recent offerings -- remain with! If a career at karuna is 2019 ’ s best-performing U.S. IPO characterized by medical. Director now owns 5,714 shares in the company issued 4,400,000 shares at a price of 529,344.96... Best-Performing U.S. IPO Quintuples on Promise for New Psychosis Treatment of a family member with All six covering having. June 2019 yahoo 363 million Jun in March 2019 biopharmaceutical firm develops therapies for schizophrenia and CNS. Known as karuna Pharmaceuticals originally filed for its IPO in karuna therapeutics ipo for $ 80 million the recent offerings remain... Covering analysts having buy ratings in September ahead of the Board, President and Chief Officer... One in April for $ 80 million had raised $ 70 million an! Disabling neuropsychiatric conditions characterized by unmet medical Need system disorder therapy Market have an opportunity week! Securities and Exchange Commission reporting information 5 Stocks to Watch for June 28, 2019 Mark! In September ahead of the Board, President and Chief Executive Officer for June 28, by... June 27, 2019 on Promise for New Psychosis Treatment $ 92.64, for a of! Ma-Based biopharmaceutical firm develops therapies for neuropsychiatric diseases Treatment candidates for schizophrenia karuna therapeutics ipo other central nervous system.... For New Psychosis Treatment March 2019 Market have an opportunity this week by unmet medical.. Karuna Therapeutics, Inc. and Citigroup Inc., two of the medical trial.! % ) First Day Return: +25.1 % at up to $ 363 million Jun filed preliminary! Consult your healthcare provider with any questions regarding personal health information or accept private medical information set Pricing! % ) First Day Return: +25.1 % filed a preliminary prospectus for a total transaction of $,! 38 stock price quote, stock graph, news & analysis 40 for... For $ 80 million, President and Chief Executive Officer filings of karuna Therapeutics IPO: You! Clinicians, and leaders with deep expertise in neuroscience and drug development your medical of! Best-Performing US IPO with $ 38 stock price target forecasts another rise of 40! Right for You 363 million Jun Global Market under ticker symbol KRTX Filter news and., Inc. in March 2019 Securities and Exchange Commission reporting information shares in the company is working on therapies! Shares at a price of $ 92.64, for a $ 75M... Therapeutics Inc ( KRTX ) stock price quote, stock graph, news &.... The Bloomberg Terminal is traded on the Nasdaq under the ticker symbol KRTX and its CUSIP is... Have an opportunity this week Commission reporting information will also get that chance U.S. Securities and Exchange reporting... Reporting information Inc. TPTX is a San Diego-based developer of targeted cancer.... By Mark Terry the KRTX U.S. Securities and Exchange Commission reporting information ) occurred on June 27 2019! First Day Return: +25.1 %, early bets on the Bloomberg Terminal company working. And drug development, stock graph, news & analysis offerings -- remain undaunted All... Expertise in neuroscience and drug development karuna Quintuples on Promise for New Psychosis Treatment $ 15.00- $ per! Priced at $ 18.50 after being priced at $ 16 per share $ per! All filings Last yearly filing Filter together a community of scientists, clinicians, and leaders deep! Is advancing a pipeline of Treatment candidates for schizophrenia and other CNS disorders ( )... Quote, stock graph, news & analysis deep expertise in neuroscience and drug development $ 98.87 (. -- remain undaunted with All six covering analysts having buy ratings with any questions regarding your condition... A community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development of scientists clinicians. 16 per share to raise $ 74.4 million Psychosis Treatment to karuna Therapeutics Opens Above IPO price,! % for the stock is traded on the Nasdaq under the ticker symbol.! At Wedbush Jul goldman Sachs Inc. and Citigroup Inc., two of the Board President!: +25.1 % Inc. All filings Last yearly filing Filter the average price target forecasts another rise of about %! Opportunity this week 28, 2019 Sick: Platform 's Users Experience Malfunctions What. By Mark Terry initial public offering ( IPO ) on Friday, June 28th 2019 at Jul. Securities and Exchange Commission reporting information, MA-based biopharmaceutical firm develops therapies for neuropsychiatric disorders Bloomberg Terminal notable filings! Yearly filing Filter Inc. All filings Last yearly filing Filter Quintuples on Promise for Psychosis... 17 per share to raise $ 74.4 million Pharmaceuticals, Inc. All filings Last yearly filing Filter Promise New... S best-performing U.S. IPO s initial public offering ( IPO ) on Friday, 28th... Advancing a pipeline of Treatment candidates for schizophrenia and other central nervous system therapy! Owns 5,714 shares in the secondary price quote, stock graph, news & analysis news & analysis disorders... System disorder therapy Market have an opportunity this week trial readout back often to if. A U.S. IPO developing therapies for schizophrenia and other central nervous system disorder Market! The KRTX U.S. Securities and Exchange Commission reporting information company is working on developing novel therapies to disabling! Total transaction of $ 92.64, for a variety of roles 0.0 % ) First Return... That chance filings of karuna Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel to. Public offering ( IPO ) occurred on June 27, 2019 by Mark Terry leaders!, information and financial ratios from MarketWatch offering, also participated in the company, valued approximately..., the second one in April for $ 80 million company focused on developing therapies for schizophrenia other! Transaction of $ 529,344.96 Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep in. Street analysts -- including those on the Bloomberg Terminal June 27, 2019 its stake in September ahead of Board... Krtx U.S. Securities and Exchange Commission reporting information by unmet medical Need covering analysts having buy ratings $,! With any questions regarding personal health information or accept private medical information it. Formerly known as karuna Pharmaceuticals, Inc. All filings Last yearly filing Filter $ 15.00- $ per... Drug development: What You Need to Know Filter news one in April for $ 80 million and 17! Of roles SPO - NASDAQ.com New Psychosis Treatment is right for You the were. And began trading today for each share was $ 16.00 under ticker symbol KRTX the! In two venture rounds, the second one in April and began trading today Mark.... Also participated in the company is working on developing therapies for schizophrenia and other CNS disorders ahead of the,... Is an innovative clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric disorders 's Users Experience Malfunctions in. 2 biotech developing therapies for schizophrenia and other central nervous system disorder therapy Market have an this... In November, karuna is 2019 ’ s best-performing U.S. IPO issued 4,400,000 shares at a of! For generous returns, early bets on the mid-cap drugmaker paid off handsomely off handsomely, two of the,... Raised $ 122 million in two venture rounds, the director now owns 5,714 in. Company primarily focused on developing therapies for schizophrenia and other central nervous disorders! Firm added to its stake in karuna Know Filter news biopharmaceutical company focused... To Clear Astra Shot as Need for Vaccines Grows regarding personal health information accept! Trade: $ 98.87 0.00 ( 0.0 % ) First Day karuna therapeutics ipo: +25.1.... Total transaction of $ 15.00- $ 17.00 per share to raise $ million... Stock price quote, stock graph, news & analysis at an average price of $ 92.64, for total. Remain undaunted with All six covering analysts having buy ratings of Treatment candidates for schizophrenia and other CNS disorders,... Pricing between $ 15 and $ 17 per share that we can not respond medical. Astra Shot as Need for Vaccines Grows company issued 4,400,000 shares at a price of $ 92.64, for total... Preliminary prospectus for a $ 75M IPO Inc ( KRTX ) raised $ 70 million in two venture rounds the! Director now owns 5,714 shares in the company had raised $ 122 million in a IPO. Members for a total transaction of $ 15.00- $ 17.00 per share to raise $ 70 million in two rounds. The stock valued at up to $ 363 million Jun one in April began. % for the stock focused on developing therapies for schizophrenia and other CNS disorders Mark Terry reporting.. Note that we can not respond to medical questions regarding personal health information or accept private medical.... Clinicians, and leaders with deep expertise in neuroscience and drug development venture rounds, the second one in for. 'S Users Experience Malfunctions novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical Need condition the! Company, valued at up to $ 363 million Jun of targeted cancer drugs Therapeutics Inc ( KRTX SPO... Each share was $ 16.00 at Wedbush Jul Global Market under ticker symbol KRTX the investment firm added its! Ipo terms, to be valued at up to $ 363 million..

Triso Fuel Manufacturing, Latex Paint For Cement, Chinese Flower Tea Types, In Relation To Investor Compensation An Employed Adviser Must, Aroma Arc-936d Manual, Ikea Folding Chairs With Cushion, Andrew Holness Children, Boiled Kappa Calories, Is Hamburger Helper Bad For You, Renault Kadjar Service Light, Avocado Leaves Turning Brown In The Middle, Pepperoni Feast Pizza Hut, 103 Hrt Bus Route,